The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report

Oral lichen planus is a chronic inflammatory mucocutaneous disease. Topical use of steroids and other immuno-modulating therapies have been tried for this intractable condition. Nowadays, tacrolimus ointment is used more commonly as a choice for treatment. However, a number of discussions have taken...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Mayu, Asoda, Seiji, Tsunoda, Kazuyuki, Soma, Tomoya, Nakagawa, Taneaki, Shirakawa, Masayori, Shoji, Hirofumi, Yagishita, Hisao, Nishikawa, Takeji, Kawana, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352802/
https://www.ncbi.nlm.nih.gov/pubmed/27368962
http://dx.doi.org/10.1007/s10266-016-0255-4
Descripción
Sumario:Oral lichen planus is a chronic inflammatory mucocutaneous disease. Topical use of steroids and other immuno-modulating therapies have been tried for this intractable condition. Nowadays, tacrolimus ointment is used more commonly as a choice for treatment. However, a number of discussions have taken place after tacrolimus was reported to be carcinogenic. This report describes a patient who applied tacrolimus ointment to the lower lip after being diagnosed with oral lichen planus in 2008, and whose lesion developed squamous cell carcinoma in 2010. Since the relationship between tacrolimus and cancer development has been reported in only a few cases, including this case report, the clinician must be careful selecting tacrolimus as a second-line treatment for oral lichen planus.

Ejemplares similares